Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives

To study the effect of sibutramine treatment on weight reduction and blood pressure improvement in three groups with antihypertensive therapy whose blood pressure was not adequately controlled with antihypertensive combination treatment.

Inclusion Criteria:

• Treated essential hypertension.
• Obesity: BMI 27-35 kg/m2

Exclusion Criteria:

• Secondary hypertension.
• Stage 3 hypertension.
• Secondary obesity; BMI > 35kg/m2.
• CAD; MI within past 6 months; NYHA stage 3 or 4 heart failure; tachyarrhythmia/atrial fibrillation; myocarditis.
• Kidney failure.
• Liver failure.
• Hyperthyroidism.
• Unstable DM.
• Carcinoma.
• Severe chronic infectious disease.
• Alcohol or drug abuse.
• Pregnancy.
• Epilepsy.
• Psychosis or treatment with antidepressants or major tranquilizers